Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy

被引：0
|
作者：
Fouzia Guestini
Katsuhiko Ono
Minoru Miyashita
Takanori Ishida
Noriaki Ohuchi
Saki Nakagawa
Hisashi Hirakawa
Kentaro Tamaki
Yasuyo Ohi
Yoshiaki Rai
Yasuaki Sagara
Hironobu Sasano
Keely May McNamara
机构：
[1] Tohoku University,
[2] Tohoku Kousai Hospital,undefined
[3] Nahanishi Clinic,undefined
[4] Sagara Hospital,undefined
来源：
Breast Cancer Research and Treatment | 2019年 / 173卷
关键词：
Triple-negative breast cancer; Neoadjuvant chemotherapy; Mechanistic markers; Drug resistance; Residual disease; Outcomes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：275 / 288
页数：13
相关论文
共 50 条
  • [1] Impact of Topoisomerase II, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Guestini, Fouzia
    Ono, Katsuhiko
    Miyashita, Minoru
    Ishida, Takanori
    Ohuchi, Noriaki
    Nakagawa, Saki
    Hirakawa, Hisashi
    Tamaki, Kentaro
    Ohi, Yasuyo
    Rai, Yoshiaki
    Sagara, Yasuaki
    Sasano, Hironobu
    McNamara, Keely May
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) : 275 - 288
  • [2] Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
    Wang, Yihua
    Zong, Beige
    Yu, Yu
    Wang, Yu
    Tang, Zhenrong
    Chen, Rui
    Huang, Man
    Liu, Shengchun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [3] Impact of Presenting Stage on Overall Survival in Patients Treated with Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
    Carroll, Jennifer F.
    Hoskin, Tanya L.
    Leon-Ferre, Roberto A.
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5132 - 5140
  • [4] Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer
    Nedeljkovic, Milica
    Tanic, Nasta
    Prvanovic, Mirjana
    Milovanovic, Zorka
    Tanic, Nikola
    BREAST CANCER, 2021, 28 (03) : 727 - 736
  • [5] Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67
    Shinichiro Kashiwagi
    Masakazu Yashiro
    Tsutomu Takashima
    Naoki Aomatsu
    Katsumi Ikeda
    Yoshinari Ogawa
    Tetsuro Ishikawa
    Kosei Hirakawa
    Breast Cancer Research, 13
  • [6] Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67
    Kashiwagi, Shinichiro
    Yashiro, Masakazu
    Takashima, Tsutomu
    Aomatsu, Naoki
    Ikeda, Katsumi
    Ogawa, Yoshinari
    Ishikawa, Tetsuro
    Hirakawa, Kosei
    BREAST CANCER RESEARCH, 2011, 13 (06)
  • [7] Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer
    Kern, Peter
    Von Minckwitz, Gunter
    Puetter, Carolin
    Pavlidou, Sofia
    Flach, Annika
    Kimmig, Rainer
    Rezai, Mahdi
    ANTICANCER RESEARCH, 2015, 35 (10) : 5479 - 5484
  • [8] Development and validation of a nomogram for predicting rapid relapse in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Ma, Tao
    Liu, Xin-Yu
    Cai, Shuang-Long
    Zhang, Jin
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [9] Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
    Ortolan, E.
    Appierto, V
    Silvestri, M.
    Miceli, R.
    Veneroni, S.
    Folli, S.
    Pruneri, G.
    Vingiani, A.
    Belfiore, A.
    Cappelletti, V
    Vismara, M.
    Dell'Angelo, F.
    De Cecco, L.
    Bianchi, G., V
    de Braud, F. G.
    Daidone, M. G.
    Di Cosimo, S.
    ESMO OPEN, 2021, 6 (02)
  • [10] Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer
    Milica Nedeljković
    Nasta Tanić
    Mirjana Prvanović
    Zorka Milovanović
    Nikola Tanić
    Breast Cancer, 2021, 28 : 727 - 736
12345